A Look At Crinetics Pharmaceuticals (CRNX) Valuation After PALSONIFY’s EU Approval And Global Expansion Progress

Crinetics Pharmaceuticals (CRNX) has been in focus after the European Commission approved PALSONIFY, its once daily oral treatment for acromegaly, expanding access across the EU and reinforcing the company’s broader international rollout plans.

See our latest analysis for Crinetics Pharmaceuticals.

Crinetics’ share price has been under pressure recently, with a 90 day share price return of a 21.9% decline and a year to date return of a 16.5% decline, even as the 1 year total shareholder return stands at 16% and the 5 year total shareholder return is around 2.4x. This suggests long term holders have still seen meaningful gains while recent momentum has faded.

If PALSONIFY’s EU approval has you thinking about where else growth focused healthcare stories might emerge next, it could be worth scanning 33 healthcare AI stocks

With PALSONIFY now cleared on both sides of the Atlantic and the stock still trading well below recent highs, the key question for you is simple: is Crinetics undervalued today, or is the market already pricing in future growth?

Most Popular Narrative: 52.7% Undervalued

Crinetics’ most followed narrative pegs fair value at $82.43, well above the last close at $39.02, which frames a wide gap investors will want to understand.

The shift in acromegaly care toward patient friendly oral therapies, combined with PALSONIFY’s positioning as a potential first medical treatment after surgery, can expand treated patient numbers across switch, naive, previously discontinued and lost to follow up groups, which would directly influence revenue growth.

Growing focus on chronic symptom control and quality of life in rare endocrine diseases, supported by PALSONIFY’s label that highlights both biochemical and symptom control, can support physician preference and patient driven demand, which may help sustain prescription volumes and future earnings.

Read the complete narrative.

Want to see what sits behind that confidence gap between price and fair value? The narrative focuses on an outlook that emphasizes revenue expansion, margin improvement and a premium future earnings multiple. Curious which specific assumptions have the biggest impact on that $82.43 figure and how analysts are thinking about 2029 earnings power?

Result: Fair Value of $82.43 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this hinges on PALSONIFY’s early launch translating into sustained prescriptions and on pipeline programs avoiding delays or setbacks that limit future product diversity.

Find out about the key risks to this Crinetics Pharmaceuticals narrative.

Another View: What The P/B Ratio Is Telling You

That fair value of $82.43 paints a very optimistic picture, but the current P/B of 4.1x is higher than the US Pharmaceuticals industry at 2.7x, even though it sits well below a peer average of 11.3x. So is the stock expensive or appealingly cheaper than its closest group?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Feeling conflicted by mixed signals on valuation and sentiment? Act now by reviewing the data, considering both perspectives, and checking the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If this Crinetics story has your attention, do not stop here. Use the Simply Wall Street Screener to spot other opportunities that could fit your style.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com